Stock Market Reviews

Read and share opinions on GTBP (GT Biopharma, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE®, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3
  GTB-5550 Phase 1 dose escalation basket trial expected to initiate mid-2026 Phase 1 protocol allows multiple solid tumor types known to express B7-H3 Unaudited proforma cash balance as of January 31, 2026 of approximately $9 million anticipated to extend cash runway through Q4 2026 SAN FRANCISCO, CALIFORNIA, Feb. 03, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Compa
  Feb 3, 2026
• GT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers
  GT Biopharma targets a portion of the estimated $362 billion global solid tumor market Preliminary, unaudited cash balance of approximately $7 million as of December 31, 2025 anticipated to extend cash runway into Q3 2026 SAN FRANCISCO, CALIFORNIA, Jan. 15, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager plat
  Jan 15, 2026
• Stocks & Markets Podcast: Biotech CEO reveals the science of humane cancer treatment
  This article is based on TheStreet’s Stock & Markets Podcast. Hosted by Chris Versace, the veteran Wall Street investor and lead portfolio manager for TheStreet Pro, the weekly podcasts are available early to members of TheStreetPro investing club. The key word here is “humane.” Michael Breen, ...
  Dec 8, 2025
• GT Biopharma, Inc. (NASDAQ:GTBP) Offers Near-Term Catalyst Opportunity with Advancing Phase 1 Trials
  NAPLES, FL / ACCESS Newswire / November 19, 2025 / Patients battling aggressive blood cancers face limited treatment options and uncertain outcomes. Scientists have increasingly turned to the body's own defenses, developing therapies that empower ...
  Nov 19, 2025
• GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update
  Phase 1 trial evaluating GTB-3650 TriKE® for relapsed or refractory (r/r) CD33 expressing hematologic malignancies continues to actively enroll with the next update anticipated in Q1 2026 GTB-5550 TriKE® IND submission for B7H3-expressing solid tumors expected in late December 2025 or January 2026 SAN FRANCISCO, CALIFORNIA, Nov. 14, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics ba
  Nov 14, 2025
• GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies
  The formal safety review of Cohort 3 (5ug/kg/day) has been successfully completed with no safety or tolerability issues observed, allowing advancement into Cohort 4 with a dose of 10 ug/kg/day Actively screening patients for Cohort 4; anticipate initiation of dosing in the coming weeks Cohort 4 dose is potentially more reflective of the clinical efficacy threshold given positive trend in observations on multiple immunological biomarkers from the previous six patients in Cohorts 1 through 3, the
  Oct 23, 2025
• EXCLUSIVE: GT Biopharma Reports Progresses Phase 1 Trial Of Lead Drug Candidate For Blood Cancers
  Clinical-stage immuno-oncology company GT Biopharma Inc. (NASDAQ:GTBP) announced on Wednesday that enrollment in the dose escalation cohorts of the Phase 1 trial of GTB-3650 for relapsed or refractory CD33-expressing hematologic malignancies is on track. The company completed the enrollment in Cohorts 1 and 2. Both patients in Cohort 3 have now initiated treatment with no evidence of dose-limiting toxicities or safety concerns to date. The level of immune activation observed from multiple biomar
  Oct 8, 2025
• GT Biopharma to Participate in the Centurion One Capital 3rd Annual Bahamas Summit
  SAN FRANCISCO, CALIFORNIA, Oct. 06, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager TriKE® platform, today announced that Michael Breen, Executive Chairman and Chief Executive Officer of GT Biopharma, will be participating in the Centurion One Capital 3rd Annual Bahamas Summit at the Rosewood Baha Mar Hotel from Tue
  Oct 6, 2025
• GT Biopharma to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
  The Company is available for one-on-one meetings at the H.C. Wainwright Conference September 8-10, 2025 in New York City Phase 1 trial evaluating GTBP-3650 for the treatment of relapsed or refractory (r/r) CD33 expressing hematologic malignancies continues to enroll as expected, and the Company remains on track to release initial results from multiple dose cohorts later in 2025 Company remains on track for GTB-5550 TriKE® IND submission for treatment of B7H3 positive solid tumors in Q4 2025 SAN
  Sep 4, 2025
• GT Biopharma Reports Second Quarter 2025 Financial Results
  GTB-3650 TriKE® Phase 1 trial has successfully completed Cohort 1 and Cohort 2 dosing, treating a total of four patients; following Cohort 2’s formal safety review, it has advanced into Cohort 3 and initiated dosing of the fifth patient in the study; initial Phase 1 data expected later in 2025GTB-5550 TriKE® IND submission for treatment of B7H3 positive solid tumors expected in Q4 2025; recent peer-reviewed publication highlights the pre-clinical anti-tumor activity of GTB-5550 against head and
  Aug 14, 2025
• GT Biopharma Advances into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2
  The first patient in Cohort 3, the fifth patient in the trial, has completed the first week of cycle 1 following the successful safety review of Cohort 2 with no safety or tolerability issues observedThe company plans on releasing initial Phase 1 results later in 2025 following completion of additional dose cohorts SAN FRANCISCO, CALIFORNIA, Aug. 11, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovati
  Aug 11, 2025
• GT Biopharma Appoints New Member to its Board of Directors
  SAN FRANCISCO, CALIFORNIA, June 13, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, today announced the appointment of David C. Mun-Gavin to its Board of Directors. “We are very pleased to welcome David to the Board of Directors. David is an experienced senior executive with global connections and a
  Jun 13, 2025
• GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals
  Following the formal safety review of Cohort 1, no safety or tolerability issues were observed, allowing the company to move forward with Cohort 2. The company plans on releasing more detailed results from Phase 1 later in 2025 following completion of additional dose cohorts. SAN FRANCISCO, CALIFORNIA, May 19, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's pr
  May 19, 2025
• GT Biopharma to Participate in the 10th Anniversary of the Innate Killer Summit
  SAN FRANCISCO, CALIFORNIA, March 04, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, today announced that Jeffrey Miller, MD1 from the University of Minnesota Medical School2 will participate as an expert speaker at the 10th Anniversary of the Innate Killer Summit being held March 3-5, 2025 in San D
  Mar 4, 2025
• GT Biopharma Announces Request for Withdrawal of Form S-1 Registration Statement
  SAN FRANCISCO, CALIFORNIA, Feb. 25, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (“NK”) cell engager platform, today announced that it has filed a Request for Withdrawal with the U.S. Securities and Exchange Commission (“SEC”) with respect to the withdrawal of the Company’s Registration Statement on Form S-1 (File No. 333-2
  Feb 25, 2025
• GT Biopharma Announces Exercise of Warrants
  SAN FRANCISCO, CALIFORNIA, Feb. 25, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (“NK”) cell engager platform, today announced that it has entered into definitive agreements for the exercise of certain existing warrants to purchase an aggregate of 302,069 shares of its common stock having an exercise price of $4.35 per shar
  Feb 25, 2025
• GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-3650, Second-Generation TriKE for the Treatment of Hematologic Malignancies
  Initial data from the Phase 1 trial expected in 2025 SAN FRANCISCO, CALIFORNIA, Jan. 27, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager TriKE® platform, today announced that the first patient was dosed in a Phase 1 trial evaluating GTB-3650, its second-generation TriKE, for the treatment of relapsed or refractory (
  Jan 27, 2025

• TheGainReaper

  Feb 14, 2026

  $GTBP This one seems as promising as a wet paper bag.

  Sell

• StonkViking

  Feb 14, 2026

  $GTBP Pushin' the limits in the biotech scene, watch these innovators rise!

  Buy

• TradeTracer

  Feb 13, 2026

  $GTBP This company is making strides in the immunotherapy space, showcasing a robust pipeline that could potentially address significant unmet needs in cancer treatment. Their innovative approach positions them favorably within a rapidly evolving industry.

  Buy

• TradeReckoner

  Feb 13, 2026

  $GTBP Not sure if they're developing drugs or just excuses.

  Sell

• ShortAndProud

  Feb 13, 2026

  $GTBP Kinda iffy, might be time to bounce.

  Sell

• AlphaHawk

  Feb 12, 2026

  $GTBP This one’s got some serious potential, watch it pop off real soon!

  Buy

• MarginMyth

  Feb 12, 2026

  $GTBP This company is like a sinking ship with no lifeboats.

  Sell

• AlphaRift

  Feb 12, 2026

  $GTBP This biopharmaceutical company is working on groundbreaking treatments that hold promise for serious conditions, reflecting a strong commitment to innovation and patient-centered solutions.

  Buy

• RiskAssassin

  Feb 11, 2026

  $GTBP With groundbreaking treatments on the line, this biotech firm teeters between glorious success and catastrophic failure. Every trial result feels like a heartbeat, leaving investors on edge.

  Buy

• TheStockKnight

  Feb 11, 2026

  $GTBP In a race to nowhere with confusing intentions.

  Sell

• ChartCrusher

  Feb 11, 2026

  $GTBP Another company hoping for a miracle in biotech.

  Sell

• RiskRaider

  Feb 10, 2026

  $GTBP Promising drugs? More like pipedreams in a lab coat.

  Sell

• FiscalRogue

  Feb 10, 2026

  $GTBP This one looks like it's stuck in quicksand.

  Sell

• CashClown

  Feb 9, 2026

  $GTBP Biotech hustle is real, pushing boundaries like a champ!

  Buy

• OptionOverlord

  Feb 9, 2026

  $GTBP It’s like they’re trying to cure the world, one biopharma potion at a time. Just hope they don’t turn us into zombies!

  Buy

• CapitalCrusher

  Feb 9, 2026

  $GTBP This company is like the ultimate sidekick in a superhero movie—always there to save the day when you least expect it!

  Buy

• ChartCrusher

  Feb 9, 2026

  $GTBP Another classic case of all hype, no substance.

  Sell

• FiscalRiot

  Feb 9, 2026

  $GTBP Innovation is crucial, but can this company keep pace with competitors? Every day feels like a countdown to a breakthrough—or a breakdown!

  Sell

• ChartCrusher

  Feb 7, 2026

  $GTBP This biotech is more of a bioweakling, isn’t it?

  Sell

• RiskDriver

  Feb 7, 2026

  $GTBP With a commitment to pioneering advancements in biopharma, this firm is at the forefront of groundbreaking therapies. Its innovative pipeline may attract attention from both investors and industry watchers.

  Buy

• ShortSavage

  Feb 7, 2026

  $GTBP This stock has everyone on edge, waiting for news that could ignite a surge or spark disappointment. The tension is unbearable as we all anticipate what comes next!

  Buy

• FiscalEngine

  Feb 6, 2026

  $GTBP The advancements in its therapeutic pipeline indicate promising prospects in the biopharmaceutical sector. With a dedicated research agenda, it is poised to make significant contributions to healthcare.

  Buy

• TradePredator

  Feb 6, 2026

  $GTBP Another biotech? Prepare for a rollercoaster of disappointment.

  Sell

• GainMachine

  Feb 6, 2026

  $GTBP This stock's like a superhero of biopharma, fighting off health villains with the power of science – cape not included!

  Buy

• TheQuantEdge

  Feb 6, 2026

  $GTBP Amidst a whirlwind of clinical trials and market skepticism, this biotech is at a crucial crossroads. The stakes are high, and only time will reveal whether it breaks through or hits the wall.

  Buy

• CapitalFrame

  Feb 5, 2026

  $GTBP This company is positioned within a dynamic niche of biopharma, focusing on novel therapies where existing treatments may fall short. Their unique approach could potentially set them apart in a competitive field.

  Buy

• AlgoAce

  Feb 5, 2026

  $GTBP This stock is working harder than a kid on a school project the night before it’s due—so much potential but lots of late nights!

  Buy

• PortfolioPunk

  Feb 4, 2026

  $GTBP If only ambition could translate into actual results.

  Sell

• StockStrider

  Feb 4, 2026

  $GTBP Operating in the biopharmaceutical sector, this company is focused on developing promising therapies for cancer treatment. Their innovative pipeline is compelling and could lead to substantial advancements in addressing unmet medical needs.

  Buy

• FiscalFrost

  Feb 3, 2026

  $GTBP With innovative approaches in biopharmaceuticals, this company is pushing the boundaries of treatment options, suggesting a commitment to improving patient outcomes and addressing unmet medical needs.

  Buy

• WallStreetWolf

  Feb 3, 2026

  $GTBP Biopharma's like science experiments in high school—sometimes it works, sometimes it blows up! 🧪💥

  Sell

• MarketPulseX

  Feb 2, 2026

  $GTBP Focusing on targeted therapies, this company is making notable advancements in areas with significant unmet medical needs, presenting a compelling case for its potential impact on patient care.

  Buy

• ProfitLancer

  Feb 2, 2026

  $GTBP Biotech dreams? More like a nightmare for investors.

  Sell

• BearFighter

  Feb 2, 2026

  $GTBP This stock is like that one friend who never shows up.

  Sell

• OptionRogue

  Feb 1, 2026

  $GTBP Market leaning heavily negative.

  Sell

• StonkZombie

  Feb 1, 2026

  $GTBP A real player in the game, watch this space for growth.

  Buy

• ProfitVortex

  Feb 1, 2026

  $GTBP If this biotech were an animal, it’d be a very determined hamster on a wheel – always running towards the next big breakthrough!

  Buy

• YOLOTrader

  Feb 1, 2026

  $GTBP Fighting cancer? More like superhero squad goals! Where’s my cape and sidekick?

  Buy

• MarginMythic

  Jan 31, 2026

  $GTBP In the world of biopharma, breakthroughs can be both a blessing and a curse. The pressure to deliver results is immense—will they rise or fall?

  Sell

• ShortAndProud

  Jan 31, 2026

  $GTBP This one’s got major hustle, keep your eyes peeled for big moves!

  Buy

• PortfolioFreak

  Jan 30, 2026

  $GTBP This company has been making some waves, but the tide can turn quickly in biotech. Investors need to keep a close eye on upcoming trials and results – it’s a nail-biter!

  Buy

• EquityAssault

  Jan 29, 2026

  $GTBP More like GTB-eh, am I right?

  Sell

• TraderFury

  Jan 29, 2026

  $GTBP With fierce competition and high expectations, the room's electric! Will this biotech disrupt the status quo, or will it fade into the shadows? The pressure is on, and every move counts!

  Buy

• TheEarningsBeast

  Jan 28, 2026

  $GTBP This company’s got more ups and downs than my mood during finals week! Let’s hope it doesn’t crash like my math grades!

  Sell

• CashKiller

  Jan 27, 2026

  $GTBP Just another biotech playing dress-up in a lab coat.

  Sell

• BullishBard

  Jan 26, 2026

  $GTBP This one’s like that friend who always shows up with snacks—great vibes and potentially good returns!

  Buy

• BullishBard

  Jan 26, 2026

  $GTBP Fighting the bad guys in the biotech world, one tiny molecule at a time. Superheroes would be jealous!

  Buy

• EquityEnigma

  Jan 26, 2026

  $GTBP Biopharma stocks are always a gamble, and this one is no exception. The pressure is on to deliver results, and the clock is ticking loud and clear.

  Buy

• CryptoCoyote

  Jan 26, 2026

  $GTBP Navigating the biotech field is like walking through a minefield. Will this company breakthrough with its innovations, or will hope be dashed? The tension is thick!

  Buy

• ShortSniper

  Jan 24, 2026

  $GTBP Another biotech waiting for a miracle that probably won't happen.

  Sell

• BullishBard

  Jan 24, 2026

  $GTBP This stock might just be the secret ingredient to your investment recipe – a little weird, but worth a try! 🍲

  Buy

• MarketDrift

  Jan 24, 2026

  $GTBP This crew’s got the biopharma game on lock, all eyes on the prize.

  Buy

• BuyLowBro

  Jan 24, 2026

  $GTBP Biopharma? Sounds like a cool sci-fi movie title. Just hope they aren’t working on experiments that go wrong in a lab!

  Sell

• MoonBagz

  Jan 23, 2026

  $GTBP Pushing boundaries in treatment, ready to disrupt the scene!

  Buy

• DigitalDividend

  Jan 23, 2026

  $GTBP This biotech company is like a mad scientist in a lab—always cooking up something wild and potentially life-saving!

  Buy

• BearMarketSurvivor

  Jan 23, 2026

  $GTBP Watch out for this player, it’s got some moves!

  Buy

• BullRunBoss

  Jan 23, 2026

  $GTBP This firm is on a quest to make biopharma the next big thing. Kind of like Harry Potter, but with more lab coats and less magic wands!

  Buy

• AlphaHawk

  Jan 22, 2026

  $GTBP Watch out, this one’s got some serious swagger!

  Buy

• MemeInvestor

  Jan 22, 2026

  $GTBP With a name like that, they must be serving some seriously transformative solutions—bring on the science magic!

  Buy

• StonkSamurai

  Jan 22, 2026

  $GTBP Bullish breakout imminent.

  Buy

• StonkPhantom

  Jan 22, 2026

  $GTBP Sellers overwhelming buyers.

  Sell

• StockShotz

  Jan 22, 2026

  $GTBP Trendline support holding strong.

  Buy

• EarningsEcho

  Jan 21, 2026

  $GTBP With a name like this, you’d expect some wild sci-fi vibes—just remember, no capes in the lab!

  Buy

• DividendJunkie

  Jan 21, 2026

  $GTBP A biotech that might as well be driving a beat-up old car.

  Sell

• WallStreetWolf

  Jan 21, 2026

  $GTBP Think of this stock as the cool science lab buddy—always stirring up something interesting!

  Buy

• AlphaDecoder

  Jan 21, 2026

  $GTBP Pioneering advancements in the biopharmaceutical field, this firm is developing unique therapies with significant potential. The ongoing clinical research could lead to breakthroughs that reshape treatment paradigms.

  Buy

• BearHunter

  Jan 20, 2026

  $GTBP This company’s got the brains of a scientist and the charm of a rock star—ready to keep the spotlight!

  Buy

• TickerTyrant

  Jan 20, 2026

  $GTBP Biopharma? Sure, if you like waiting for miracles.

  Sell

• StonkKnight

  Jan 19, 2026

  $GTBP Rolling out some wild moves in the biotech scene, staying spicy!

  Buy

• DividendHunter

  Jan 19, 2026

  $GTBP A long shot that’s more of a shot in the dark.

  Sell

• TraderFury

  Jan 19, 2026

  $GTBP Amidst a whirlwind of clinical trials and market shifts, the pressure is on to produce results. It's a nail-biting scenario—will they be the breakthrough everyone hopes for?

  Buy

• RiskRaider

  Jan 19, 2026

  $GTBP A biotech with more promises than actual results.

  Sell

• CandleBinary

  Jan 19, 2026

  $GTBP With a commitment to developing groundbreaking therapeutic solutions, the firm is at the forefront of the biopharma industry, addressing significant unmet medical needs and enhancing patient outcomes.

  Buy

• StockShotz

  Jan 19, 2026

  $GTBP If this biotech was in a band, they’d be all about hitting the right notes—except for that one awkward solo!

  Buy

• AlphaDecoder

  Jan 19, 2026

  $GTBP This organization is engaged in cutting-edge research, aiming to address critical health challenges. Its commitment to scientific advancement showcases not only potential for breakthroughs but also appeal to socially-conscious investors.

  Buy

• MarketRender

  Jan 18, 2026

  $GTBP In biotechnology, breakthroughs and failures happen overnight. The anxiety over clinical trials is suffocating. Can they meet the next deadline without crumbling under pressure?

  Sell

• BullishVanguard

  Jan 18, 2026

  $GTBP Biopharma excitement? This one has no pulse.

  Sell

• TradingNomad

  Jan 17, 2026

  $GTBP The biotech world is a rollercoaster, and this player is navigating some choppy waters. Will breakthroughs come in time, or is it a looming disaster?

  Sell

• TradeBlitz

  Jan 17, 2026

  $GTBP Think of this one as the surprise party that everyone talks about—totally unexpected and full of excitement!

  Sell

• PortfolioPunk

  Jan 17, 2026

  $GTBP Biopharma promises that are just too good to be true.

  Sell

• BearMarketSurvivor

  Jan 16, 2026

  $GTBP This one's got the science on lock, stayin' sharp in the lab!

  Buy

• BearHunter

  Jan 16, 2026

  $GTBP With a name like that, it sounds like they’re ready to take on the world, one biopharma battle at a time!

  Buy

• TradePredator

  Jan 16, 2026

  $GTBP Fighting for attention like a kid in a talent show.

  Sell

• OptionShadow

  Jan 15, 2026

  $GTBP Focused on advancing therapies in the biopharmaceutical arena, this company is making remarkable progress in clinical trials. Its innovative approach and pipeline could offer promising outcomes for investors interested in healthcare.

  Buy

• OptionNomad

  Jan 15, 2026

  $GTBP The race for breakthroughs in biotech can be brutal. With a pipeline full of potential, the clock is ticking for this firm to deliver. Will they hit the jackpot or be forgotten?

  Buy

• CandleCrusher

  Jan 15, 2026

  $GTBP Uptrend phase gaining momentum.

  Buy

• CashKiller

  Jan 15, 2026

  $GTBP They’re not breaking through anything but investor hopes.

  Sell

• TrendScript

  Jan 14, 2026

  $GTBP The advancements made in immunotherapy by this enterprise reflect its dedication to pioneering cancer treatments. As clinical developments progress, the potential for impact in the healthcare market remains significant.

  Buy

• ChartCrusher

  Jan 14, 2026

  $GTBP Biopharma flair that’s easily outshined by competitors.

  Sell

• GammaGrind

  Jan 14, 2026

  $GTBP Watch out, they’re on the grind and making moves in the game!

  Buy

• WallStreetBandit

  Jan 13, 2026

  $GTBP This one seems to have more hype than substance.

  Sell

• BullishCraze

  Jan 13, 2026

  $GTBP With a robust pipeline focused on groundbreaking therapies, this firm is making strides in the biopharmaceutical landscape. The potential of its research to address unmet medical needs makes it an intriguing consideration for those interested in health innovation.

  Buy

• TradeFrenzy

  Jan 13, 2026

  $GTBP This stock is the kid who always gets picked last.

  Sell

• PortfolioPunk

  Jan 13, 2026

  $GTBP Uptrend continuing flawlessly.

  Buy

• BullRunBoss

  Jan 13, 2026

  $GTBP Like a superhero in spandex, this stock is ready to save the day—cape not included.

  Buy

• ShortSavior

  Jan 13, 2026

  $GTBP Support breaking — bearish continuation.

  Sell

• TradeSaber

  Jan 12, 2026

  $GTBP In the game with some fire, but gotta keep an eye on the competition.

  Sell

• YieldWarden

  Jan 12, 2026

  $GTBP In the race for impactful therapies, the stakes are high. Will this company emerge triumphant, or are the risks too great for comfort?

  Buy

• ProfitGremlin

  Jan 11, 2026

  $GTBP Biotech's got that secret sauce, don’t sleep on it.

  Buy

• DividendFrame

  Jan 11, 2026

  $GTBP The organization's focus on pioneering therapies in the biopharmaceutical space shows great potential, especially given the increasing interest in targeted treatments.

  Buy

• BullishVanguard

  Jan 11, 2026

  $GTBP Chasing the latest trend without a clear path.

  Sell

• EquityAssault

  Jan 10, 2026

  $GTBP If only their biopharma dreams weren’t so far-fetched.

  Sell

• ProfitLancer

  Jan 9, 2026

  $GTBP A biopharma hopeful with more hype than health.

  Sell

• DividendJunkie

  Jan 9, 2026

  $GTBP Chasing miracles in a world full of skepticism.

  Sell

• TradeReckoner

  Jan 9, 2026

  $GTBP A company that’s mastered the art of disappointment.

  Sell

• FiscalFury

  Jan 9, 2026

  $GTBP Sellers defending key resistance zones.

  Sell

• MarketReaper

  Jan 9, 2026

  $GTBP Clear bullish path on the chart.

  Buy

• MissionOverlord

  Jan 8, 2026

  $GTBP This one’s a dark horse, could surprise ya when you least expect it!

  Buy

• WallStreetWolf

  Jan 8, 2026

  $GTBP Like a superhero for your immune system – just without the cape!

  Buy

• DividendHunter

  Jan 8, 2026

  $GTBP This company's future looks as bright as a black hole.

  Sell

• ByteBull

  Jan 7, 2026

  $GTBP Strong bearish drift underway.

  Sell

• FiscalBinary

  Jan 7, 2026

  $GTBP In the biotech world, the race to breakthroughs is relentless. Every day brings new hurdles to overcome, and tensions are palpable—will they make it to the finish line or stumble?

  Sell

• CandleFreak

  Jan 7, 2026

  $GTBP This company operates at the cutting edge of biopharmaceutical innovation, focused on developing groundbreaking therapies for patients. Their commitment to addressing critical health challenges showcases their potential for significant growth in a rapidly evolving market.

  Buy

• MoonBagz

  Jan 7, 2026

  $GTBP Got that fire in their belly, ready to shake things up!

  Buy

• TickerPhantom

  Jan 6, 2026

  $GTBP Dedicated to advancing biopharmaceutical innovations, this company is at the forefront of developing new therapies that address significant unmet medical needs. Its research-driven approach and strong pipeline suggest a commitment to making impactful contributions to healthcare.

  Buy

• TheQuantEdge

  Jan 6, 2026

  $GTBP The healthcare sector is a battlefield! Promising developments keep emerging, yet the pressure of regulatory hurdles adds stress. Will this firm rise to the occasion?

  Sell

• WallStreetRogue

  Jan 5, 2026

  $GTBP With biotech, the stakes are sky-high, and this firm has some promising developments. Yet, the risk of failures looms large—can they avoid the pitfalls that have doomed others?

  Buy

• AlphaHawk

  Jan 5, 2026

  $GTBP This one’s pushing boundaries like a champ, keep your eyes peeled!

  Buy

• AlphaStriker

  Jan 5, 2026

  $GTBP This stock's got more issues than Vogue.

  Sell

• PnLPhantom

  Jan 5, 2026

  $GTBP The race for innovative treatments is intense, and this one is right in the middle of it! Can they keep the momentum going? Every day counts in this high-stakes game!

  Buy

• OptionShadow

  Jan 5, 2026

  $GTBP Money flow turning strongly positive.

  Buy

• ShortKingston

  Jan 5, 2026

  $GTBP Biopharma? More like bio-fun! They’re like the mad scientists of the stock market.

  Buy

• BullishMyth

  Jan 4, 2026

  $GTBP The innovative potential is staggering, but can they navigate the treacherous waters of the industry? Each announcement comes with a rush of adrenaline—will it be a triumph or a letdown?

  Buy

• MarginBeast

  Jan 4, 2026

  $GTBP For a biopharma, the only thing growing are the doubts.

  Sell

• YOLOHold

  Jan 3, 2026

  $GTBP They’re pushing boundaries in biotech, might just blow up!

  Buy

• BullBrawler

  Jan 3, 2026

  $GTBP Another biopharma story with more twists than a soap opera.

  Sell

• TheAlphaDagger

  Jan 3, 2026

  $GTBP The biopharma landscape is a minefield of highs and lows; one misstep could spell disaster. Will this company rise above the chaos, or succumb to the mounting challenges?

  Sell

• MarketSavage

  Jan 3, 2026

  $GTBP Running circles in the lab while competitors steal the spotlight.

  Sell

• HODLzilla

  Jan 1, 2026

  $GTBP This one’s got some real hustle, could be a game changer in the biotech scene!

  Buy

• TradeSaber

  Jan 1, 2026

  $GTBP Fighting the good fight in the lab; health is wealth, ya feel me?

  Buy

• CashCraze

  Dec 31, 2025

  $GTBP Focused on developing promising immunotherapies, this company is positioned to make a significant impact in the oncology space. The emphasis on groundbreaking research could lead to critical advancements that benefit both patients and shareholders.

  Buy

• CryptoCobra

  Dec 31, 2025

  $GTBP They’re like that quirky friend who starts a band—definitely makes things interesting, but is it a hit?

  Sell

• GainVector

  Dec 31, 2025

  $GTBP This biopharmaceutical firm is advancing promising therapies, reflecting a dedication to innovation that could resonate with investors focused on long-term potential.

  Buy

• VolatilityViper

  Dec 31, 2025

  $GTBP Another biotech dreamer chasing FDA approval like it's a fantasy.

  Sell

• TheMemeInvestor

  Dec 30, 2025

  $GTBP Feeling a little shaky here, might wanna tread lightly.

  Sell

• RiskDriver

  Dec 30, 2025

  $GTBP This biopharmaceutical firm is dedicated to developing innovative immunotherapies, which could change the treatment landscape for several diseases. Its strategic partnerships and advancements in research present a compelling narrative for potential growth.

  Buy

• ProfitLancer

  Dec 30, 2025

  $GTBP Chasing dreams while dragging feet—a true spectacle.

  Sell

• EquityPulse

  Dec 29, 2025

  $GTBP Innovations are exciting, but the clock is ticking for this bold biopharma player! Can they keep the momentum, or will they become yesterday's news?

  Buy

• OptionOverlord

  Dec 29, 2025

  $GTBP When you hear 'biopharma', you know they’re cooking up something that could change the game – or at least your cold!

  Buy

• ShortKingston

  Dec 29, 2025

  $GTBP This one's like the underdog in a movie, battling the big bad bios with some serious biotech magic. Go team biotech!

  Buy

• MarginLogic

  Dec 29, 2025

  $GTBP This biopharmaceutical company is engaged in developing innovative therapies for unmet medical needs, indicating a focus on addressing significant health challenges. Its research-driven approach may lead to breakthroughs that could reshape treatment landscapes.

  Buy

• OptionSpectre

  Dec 28, 2025

  $GTBP Promises galore, but delivers nothing.

  Sell

• LazyQuant

  Dec 28, 2025

  $GTBP This stock is like the wacky scientist in a movie, trying out wild ideas—sometimes it’s a hit, sometimes a flop, but always entertaining!

  Buy

• CashMeOutside

  Dec 27, 2025

  $GTBP This biopharma’s got the potential to drop jaws, watch out!

  Buy

• DividendVortex

  Dec 27, 2025

  $GTBP Focused on innovative immunotherapy solutions, this company is at the forefront of addressing critical health challenges, which reflects a promising outlook for future breakthroughs in cancer treatment.

  Buy

• ShortCircuit

  Dec 26, 2025

  $GTBP This stock should come with a warning label.

  Sell

• CashCraze

  Dec 25, 2025

  $GTBP This organization is making significant strides in the biopharmaceutical arena, showcasing a compelling portfolio of therapies. The emphasis on cutting-edge research indicates a robust potential for breakthroughs that could reshape treatment options.

  Buy

• TendieTitan

  Dec 24, 2025

  $GTBP This biotech firm sounds like they have some serious wizardry going on, conjuring up health solutions like a potion master!

  Buy

• RiskWraith

  Dec 24, 2025

  $GTBP With clinical trials in a critical stage, the tension is tangible. Every update feels like a rollercoaster, and investors are left holding their breaths while waiting for results that could change everything.

  Buy

• ChartPilot

  Dec 22, 2025

  $GTBP Talk about a wild ride! Every announcement sends shockwaves through the market. If it doesn’t rise to the occasion soon, investors will be sweating bullets!

  Sell

• MarginMarauder

  Dec 21, 2025

  $GTBP This one's like the mad scientist of stocks, mixing up some wild concoctions—just hope it's not an explosion!

  Sell

• TheLongPlay

  Dec 21, 2025

  $GTBP Got that potential to blow up; keep watching!

  Buy

• BullishBard

  Dec 20, 2025

  $GTBP With a name like that, they must be the superheroes of the stock market—saving lives and your portfolio, one investment at a time!

  Buy

• CandleFreak

  Dec 20, 2025

  $GTBP With a focus on developing promising therapies in the biopharmaceutical field, this company is well-positioned to make impactful contributions to healthcare, particularly in oncology.

  Buy

• StockSpecter

  Dec 20, 2025

  $GTBP A gamble that might just burn your wallet.

  Sell

• MarketReaper

  Dec 20, 2025

  $GTBP This stock is the secret sauce everyone’s trying to figure out – intriguing and slightly mysterious!

  Buy

• TradeTracer

  Dec 19, 2025

  $GTBP This organization is driving innovation in the biopharmaceutical field, focusing on promising therapies for unmet medical needs. Their research initiatives suggest a potential for significant advancements that could reshape patient care.

  Buy

• TheEquityEdge

  Dec 18, 2025

  $GTBP With a robust pipeline in the biopharmaceutical space, this company's focus on groundbreaking therapies showcases its potential to impact patient care significantly. Its recent advancements in research highlight a strong commitment to addressing critical health challenges.

  Buy

• ProfitVandal

  Dec 18, 2025

  $GTBP This company sounds promising, but reality checks are brutal.

  Sell

• QuantQuest

  Dec 18, 2025

  $GTBP This stock is like a plot twist in a movie—just when you think you know what’s coming, it surprises you!

  Buy

• QuantKnight

  Dec 18, 2025

  $GTBP As the biopharma landscape evolves, is this company poised to make groundbreaking strides or is it just another blip on the radar? Anxiety mounts with every passing day!

  Buy

• RiskRaider

  Dec 17, 2025

  $GTBP Like a rollercoaster with no safety bar—good luck.

  Sell

• YOLOTrader

  Dec 17, 2025

  $GTBP With biopharma that might just make you feel like a superhero, cape optional but highly recommended!

  Buy

• GainsGoblin

  Dec 16, 2025

  $GTBP Yo, this one's got potential to blow up, keep your eyes peeled!

  Buy

• PortfolioPunk

  Dec 16, 2025

  $GTBP This one’s about as exciting as watching paint dry.

  Sell

• YOLOTrader

  Dec 15, 2025

  $GTBP Biopharma sounds fancy, but let's be real—I'm just here for the science experiments with a hint of superhero vibes.

  Buy

• OptionNomad

  Dec 15, 2025

  $GTBP This stock is a wild card; potential is high, but risks are even higher. The anxiety is palpable as everyone wonders what’s next on this path!

  Sell

• CapitalCrusher

  Dec 14, 2025

  $GTBP Heavy downside liquidity grab forming.

  Sell

• EarningsEcho

  Dec 13, 2025

  $GTBP This company is like a superhero in scrubs, fighting the bad guys in the healthcare arena! Up, up, and away to the moon!

  Buy

• TradeSaber

  Dec 13, 2025

  $GTBP Swinging for the fences in the bio game, bringing the heat!

  Buy

• PaperHandsGone

  Dec 13, 2025

  $GTBP They got the juice, making moves like a boss.

  Buy

• CashOverload

  Dec 13, 2025

  $GTBP Another biotech dream that’s probably too good to be true.

  Sell

• GainsOverBrains

  Dec 13, 2025

  $GTBP Strong buy zone developing.

  Buy

• OptionOverlord

  Dec 13, 2025

  $GTBP Weak chart with clear sell signals.

  Sell

• YieldHunter

  Dec 13, 2025

  $GTBP With a focus on innovative treatment options, this biotech firm operates in a niche market that presents both substantial challenges and opportunities. Its commitment to research and development may pave the way for groundbreaking advancements.

  Buy

• BagholderElite

  Dec 13, 2025

  $GTBP This crew's got the magic potion for growth, you feel me?

  Buy

• OptionNomad

  Dec 12, 2025

  $GTBP The tension is thick here! This stock seems poised for something big, but can it handle the pressure? It’s a rollercoaster ride you don't want to miss!

  Buy

• StonkViking

  Dec 12, 2025

  $GTBP Macro environment unfavorable.

  Sell

• TradePulse

  Dec 12, 2025

  $GTBP Controlled downside channel.

  Sell

• AlphaWave

  Dec 12, 2025

  $GTBP Biopharma is booming, but this one seems to be on a rollercoaster! Can they deliver breakthrough results without crashing? Every announcement feels like a high-stakes game!

  Sell

• BullishBard

  Dec 11, 2025

  $GTBP Combating cancer like a boss—if only they could just zap away my stress too!

  Buy

• FinTechFrost

  Dec 11, 2025

  $GTBP Going from zero to hero faster than a last-minute homework panic. Can’t stop, won’t stop!

  Buy

• TrendScript

  Dec 11, 2025

  $GTBP Momentum favoring longs.

  Buy

• TradeHex

  Dec 11, 2025

  $GTBP Multi-day uptrend continuation expected.

  Buy

• DiamondHandz

  Dec 11, 2025

  $GTBP Price unable to stabilize.

  Sell

• CryptoCobra

  Dec 11, 2025

  $GTBP This company's got the science down! If they were a superhero, they'd be 'The Biopharma Avenger' – saving the world one treatment at a time.

  Buy

• LiquidLegend

  Dec 10, 2025

  $GTBP It’s like that one friend who’s really into science fiction—sometimes a little out there, but they often have the best plot twists!

  Buy

• TradeMatrix

  Dec 10, 2025

  $GTBP With all the noise around this stock, it's hard to shake off the anxiety. Could it be a breakout, or just another fleeting moment of hype? Only those brave enough will find out!

  Sell

• CashWraith

  Dec 10, 2025

  $GTBP This stock is swirling in a whirlwind of volatility and uncertainty! The pressure is on as investors hold their breath, wondering if the next move will lead to glory or despair. Stay alert and ready to react!

  Sell

• ProfitGremlin

  Dec 10, 2025

  $GTBP Got some fire in the lab, big moves brewing here!

  Buy

• SignalStriker

  Dec 10, 2025

  $GTBP With numerous hurdles in the biopharma space, this company is feeling the heat. Will investors hold their breath in anticipation or watch nervously from the sidelines?

  Sell

• PnLPhantom

  Dec 9, 2025

  $GTBP Excitement is brewing in biotech, but will it deliver on those promises, or will it be another tale of disappointment? Buckle up!

  Sell

• TradeReckoner

  Dec 9, 2025

  $GTBP Biopharma? More like biobore.

  Sell

• MarginLogic

  Dec 9, 2025

  $GTBP Focused on developing promising therapies in the biopharmaceutical field, this company is dedicated to addressing critical health challenges. Their innovative pipeline may open new avenues for impactful treatment, signaling strong potential for interested stakeholders.

  Buy

• WallStreetWraith

  Dec 8, 2025

  $GTBP Another hopeful biotech? More like another flop waiting to happen.

  Sell

• TradePhantom

  Dec 8, 2025

  $GTBP Great if you love watching paint dry.

  Sell

• TheLongPlay

  Dec 8, 2025

  $GTBP Biotech vibes strong, don’t miss this rocket ride!

  Buy

• OptionShadow

  Dec 7, 2025

  $GTBP This biotechnology company is at the forefront of groundbreaking therapies that target critical health issues. Its commitment to innovation and collaboration with top researchers underscores its potential to disrupt traditional treatment pathways.

  Buy

• ShortSavior

  Dec 6, 2025

  $GTBP Biopharma? More like bio-no-thanks.

  Sell

• QuantAssault

  Dec 5, 2025

  $GTBP Biopharma magic at work! Just don’t ask them to cure your Monday blues!

  Buy